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Abstract. TSG-6 cDNA was isolated by differential
screening of a X cDNA library prepared from tumor
necrosis factor (TNF)-treated human diploid FS-4
fibroblasts. We show that TSG-6 mRNA was not de-
tectable in untreated cells, but became readily induced
by TNF in normal human fibroblast lines and in pe-
ripheral blood mononuclear cells. In contrast, TSG-6
mRNA was undetectable in either control or TNF-
treated human vascular endothelial cells and a variety
of tumor-derived or virus-transformed cell lines. The
sequence of full-length TSG-6 cDNA revealed one ma-
jor open reading frame predicting a polypeptide of
277 amino acids, including a typical cleavable signal
peptide. The NH2-terminal half of the predicted TSG-6
protein sequence shows a significant homology with a
recently identified family of hyaluronate (HA)' bind-
ing proteins includes the cell surface adhesion re-
ceptor CD44, cartilage link protein, and proteogly
can core proteins (Neame et al., 1987; Goldstein et al.,
1989; Stamenkovic et al., 1989). The conserved, homolo-
gous regions include the HA binding domains in all ofthese
proteins (Goetinck et al., 1987; Perin et al ., 1987). CD44,
also termed Hermes antigen (Jalkanen et al ., 1986), Pgp-1
(Hughes et al ., 1981), or H-CAM (Culty et al., 1990), is best
known as an integral membrane protein responsible for the
interaction between lymphocytes and high endothelial cells
in the gut-associated lymphoid tissues during lymph node
homing (Jalkanen et al ., 1986). CD44 is now known to be
identical to the cellular hyaluronate receptor (Aruffo et al.,
1990; Culty et al., 1990; Miyake et al., 1990), mediating the
adhesion of a variety ofdifferent cells to HA in the extracel-
lular matrix and on cell surfaces (Underhill, 1989) . While
CD44 is the principal cell surface receptor for HA, all func-
tions of this adhesion receptor may not depend on its ability
1. Abbreviations used in thispaper: CPC, cetylpyridinium chloride; EDC,
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide; HA, hyaluronate; huPBL,
human peripheral blood leukocytes; HUVEC, human umbilical vein endo-
thelial cells; IL-1, interleukin 1; TNF, tumor necrosis factor; TSG, TNF-
stimulated gene.
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region implicated in hyaluronate binding, present in
cartilage link protein, proteoglycan core proteins, and
the adhesion receptor CD44 . The most extensive se-
quence homology exists between the predicted TSG-6
protein and CD44. Western blot analysis with an an-
tiserum raised against a TSG-6 fusion protein detected
a 39-kD glycoprotein in the supernatants of TNF-
treated FS-4 cells and of cells transfected with TSG-6
cDNA. Binding of the TSG-6 protein to hyaluronate
was demonstrated by coprecipitation. Our data indi-
cate that the inflammatory cytokine (TNF or IL-1)-
inducible, secretory TSG-6 protein is a novel member
of the family of hyaluronate binding proteins, possibly
involved in cell-cell and cell-matrix interactions dur-
ing inflammation and tumorigenesis.
to bind HA. Most notably, the function of CD44 as a lym-
phocyte homing receptor appears to involve the binding of
CD44 to mucosal vascular addressins, and not to HA (Jalka-
nen et al ., 1987; Culty et al., 1990) . CD44 also acts as a
receptor for type I and IV collagen (Carter and Wayner,
1988). The fact that CD44 (or closely related proteins) is
(are) expressed on a large variety ofmammalian tissues (Un-
derhill, 1989), together with other accumulated evidence,
suggest that CD44 mediates many different cell adhesion
events involving cell-substratum or cell-cell interactions
(Aruffo et al., 1990; Culty et al., 1990; Miyake et al., 1990) .
The proteoglycan core protein (aggrecan) and link protein
are important structural components of the extracellular ma-
trix of cartilage. Aggrecan (Doege et al., 1990b) and the
closely related proteoglycan core protein of fibroblasts (ver-
sican) (Zimmermann and Ruoslahti, 1989) contain at their
amino terminus HA binding motifs, which were originally
defined in link protein (Doege et al ., 1986). In cartilage,
aggrecan forms a ternary complex with both HA and link
proteins, which determinesthe structural integrity ofthe ex-
tracellular matrix of cartilage (Hascall and Hascall, 1981;
Kimata et al ., 1982) .
In this paper we report the identification ofa new member
of the family of HA binding proteins, provisionally termed
545TSG (for TNF-stimulated gene)-6. TSG-6 DNA has been
isolated from a cDNA library prepared from tumor necrosis
factor-ci (TNF-a)-treated human FS-4 diploid foreskin fi-
broblasts (Lee etal., 1990). TSG-6 mRNA was undetectable
in untreated FS-4 cells, but became markedly elevated af-
ter treatment with TNF. TSG-6 mRNA was also inducible
by interleukin 1 (IL-1), the phorbol ester 12-O-tetradeca-
noylphorbol 13-acetate, calcium ionophore A23187, and
double-stranded RNA, but not by various growth factors, in-
terferons, and some other agents (Lee etal., 1990). The rela-
tively selective inducibility of TSG-6 mRNAby the inflam-
matory cytokines TNF and IL-1 prompted us to sequence the
full-length cDNA and analyze TSG-6 mRNA expression in
different types of cells. We report here that the protein en-
coded by TSG-6 cDNA showed a significant sequence ho-
mology with members of the family of HA binding proteins,
and especially with CD44. Our data indicate that TSG-6 is
a TNF (and IL-1)-inducible, secretory HA binding protein.
TSG-6 mRNA is readily inducible in normal fibroblasts and
peripheral blood leukocytes, but not in a variety of tumor-
derived or virus-transformed cell lines. Its high degree of se-
quence homology with the N112-terminal half of CD44, to-
gether with its inducibility by TNF and IL-1, suggest that
TSG-6 functions as a regulator of cell-cell and cell-matrix
interactions during inflammation and tumorigenesis.
Materials andMethods
Cell Cultures
Thenormalhuman diploid foreskin fibroblasts (FS-4, FS-48, and FS-49 cell
lines), isolated in this laboratory, were maintained in MEM supplemented
with 5 % FBS. The normal human diploid fetal lung fibroblast line WI-38,
and the SV-40-transformed WI-38 cell lin& (WI-38 VA13) were received
from the American Type Culture Collection (Rockville, MD) and grown in
Eagles' MEMsupplementedwith 10% FBS. TheSV-40-transformed human
skinfibroblast lina13M-637 (obtained from the HumanGenetic MutantCell
Repository, Camden, NJ) and the human cutaneous malignant melanoma
cell line SK-MEL-19, kindly provided by Dr. Alan Houghton (Memorial
Sloan-Kettering Cancer Center, New York), were grown in MEM sup-
plemented with 10% FBS. Thehumanmacrophage-like cell line, U937, was
grown in RPMI-1640 medium containing 20% FBS. The human rhab-
domyosarcoma (A673), human lung carcinoma (A549), and human colon
adenocarcinoma cell lines (Colo205 and HT29) were maintained in DME
containing 10% FBS. Thehuman umbilical vein endothelialcells (HUVEC)
were kindly provided by Dr. Richard Levin (New York University Medical
Center, New York) and maintained in a-MEM supplemented with 20%
FBS and basic fibroblast growth factor (10 ng/ml; a gift from Dr. D.
Moscatelli, Department of Cell Biology, New York University Medical
Center). HUVEC cultures were used at passage 5. Mononuclear cells from
human peripheral blood leukocytes (huPBL) from the blood of healthy
donors were isolated by centrifugation on Ficoll-Hypaque gradients (Iso-
lymph; Gallard-Schlesinger Chemical Manufacturing Corp., Carle Place,
NY) and cultured in RPMI-1640 medium containing 10% FBS.
Northern Blot Analysis
Nonadherent U937 cells were treated with TNF (20 ng/tnl) for 4 h at a cell
density of 106 cells/ml. HuPBL (1 x 106 mononuclear cells/nil) were
treated with TNF (20 ng/ml), Con A (5 uglml), or phytohemagglutinin (2
1xglml) for 16 h. All other adherent cell lines were used when confluent,
and were treated with TNF for 4 h. Cell pellets were prepared, and in most
cases total RNA was isolated by the acid guanidium-thiocyanate-phenol-
chloroform extraction method (Chomczynski and Sacchi, 1987), except
for the normal fibroblast cell lines (FS-4, FS-48, FS-48, and WI-38), for
which a method described elsewhere was used (Lin and Vil6ek, 1987).
Northern blots were prepared and probed according to Maniatis et al.
(1982) . 32p-Labeled probes that detect TSG-6 mRNA and the invariant
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pHe7 transcripts were prepared with the aid ofa nick translation kit (Boeh-
ringer Mannheim Corp., Indianapolis, IN).
Sequence Analysis
Among the six X clonesthat cross-hybridized with TSG-6cDNA (Lee et al.,
1990), clone X5 had the longest insert (1.4 kb) and was therefore used for
full-length cDNA sequence analysis. The 1.4-kb cDNA insert of clone X5
was subcloned into the EcoRI site ofM13mp18 bacteriophage in bothorien-
tations. To insure fidelity of sequence determination, directional deletion
clones were generated by the ExoIWSI method (Henikoff, 1984) in both
directions within the M13 clones. Thedeletion clones were then used to de-
termine the nucleotide sequence, utilizing the Sequenase kit available from
United States Biochemical Corp. (Cleveland, OH).
Preparation ofBacterial Fusion Proteins
To express a bacterial fusion protein of TSG-6, we used an EcoRI cDNA
insert from clone X6 (Lee et al., 1990). Clone X6 contains a cDNA insert
that lacks 402 by at the Yend and 4 by at the 3' end of the TSG cDNA se-
quence shown in Fig. 1 A. An EcoRl-BamHI (406 bp) restriction fragment
(which encodes the portion of TSG-6 open reading frame spanning from
Ile11s to Asp2°a) was isolated from the EcoRI cDNA insert of clone X6 and
cloned into the same restriction sites in the polylinker downstream of, and
in frame with, a portion (37 kD) ofthe Fscherichia coli TrpE open reading
frame in the pATH21 vector (Sprindler et al., 1984), resulting in the
TrpE/TSG-6 expression plasmid pATH-TSG-6. The same restriction frag-
ment (EcoRI-BamHI) was also inserted into the pEX34A bacterial expres-
sion vector, resulting in the MS2/TSG-6 expression plasmid pEX-TSG-6.
pEX34A is a derivative of pEX29 (Klinkert et al., 1985; Strebel et al.,
1986), which permits the production of foreign proteins fused to the NH2-
terminal part of the MS2 polymerase and controlled by the temperature-
inducible XPL promoter. The two expression plasmids (PATH-TSG-6 and
pEX-TSG-6) were transfected into competent E. coli HB101 and E. coli
AHAtrp cells (Remaut et al., 1981), respectively. Cells transformed with
pATH-TSG-6 were grown and induced by the addition of 3-ß-indolacrylic
acid (Sigma 11625) (Sprindler et al., 1984), and E. coli transformed with
pEX-TSG-6 were induced by raising the incubation temperature (Remaut et
al., 1981). Purification of both fusion proteins was done essentially as de-
scribed by Strebel etal. (1986). Briefly, cells from a 1L culturewere pelleted
and washed with TEN (10 mM Tris-HCI, pH 8.0, 1 mM EDTA, and 0.5 M
NaCI), lysed with lysozyme (5 mg/ml), and finally broken by sonication.
Insoluble material was recovered by centrifugation (30 min, 20,000 g) and
extracted sequentially with 20 ml of 3 M urea and 5 ml of 7 M urea each
for 30 min at 37°C. The 7 M urea extract containing the fusion protein was
further purified by preparative 10% SDS-PAGE. After electrophoresis the
fusion protein was excised from the gel, electroeluted, and concentrated as
needed. The purity of the electroeluted fusion protein was checked on ana-
lytical gels. After the second round of electroelution, we obtained highly
purified fusion proteins with no detectable E. coli protein bands on SDS-
PAGE (data not shown).
Preparation and Purification ofPblyclonal Antisera
Specificfor TSG-6Protein
Rabbits were first immunized with -200 wg of the TrpE/TSG-6 fusion pro-
tein suspended in Freund's complete adjuvant, and boosted at intervals of
2-3 wk with the same amount ofprotein in Freund's incomplete adjuvant.
All injections were performed subcutaneously, except for the final boost
which was done intravenously. Rabbits were bled 6 d after immunizations.
Sera were analyzed by inununoblotting as described (Towbin et al., 1979).
To obtain antibodies specific for the TSG-6-coded domains in the
TrpE/TSG-6 fusion protein, the antiserum was purified on an affinity
column to which the MS2/TSG-6 fusion protein was coupled. The affinity
column was prepared as follows. 5 mg ofpurified MS2/TSG-6 fusion pro-
tein was dialyzed extensively against 0.5 M NaCI and mixed with 3 ml of
EAH-Sepharose 4B beads (Pharmacia Fine Chemicals, Piscataway, NJ).
After adjusting pH to 4.5, 40 mg 1-(3-dimethylaminopropyl)-3-ethylcarbo-
diimide hydrochloride (EDC) (Aldrich Chemical Co., Milwaukee, WI)/ml
H2O was added dropwise under constant stirring. The coupling reaction
was then allowed to proceedovernight under constant stirring. 200 pl acetic
acid was then added and the beads were incubated for another 4 h to block
the remaining amino groups on the matrix. The matrix material was washed
several times alternately with a buffer containing 0.1 M acetate, pH 4.0,
5460.5 M NaCI and a buffer containing 0.1 M NaHC03 , pH 8.3, 0.5 M NaCl,
and finally suspended and stored in TBS (20mM Tris-HCI, pH 7.5, 0.5 M
NaCl) . For affinity purification ofantiserum, 0.5 ml of MS2/TSG-6 Seph-
arose beads, equilibrated with TBS containing 0.05% Tween-20 (TTBS),
was mixed and incubated with 1 nil of antiserum at 4°C overnight under
constant rotation . The reaction mixture was then washed three times with
3 ml TTBS. To elute bound antibody specific for the TSG-6 protein, 1 ml
of0.1 M glycine-HCI buffer, pH 2 .5, was added to the beads, andthe super-
natant was collected and immediately neutralized with solid Tris .
Stable TlransfectionofTSG-6cDNA into
GM-637 Cells
An expression plasmidpSVTSG-6 was constructed by replacing the 0-tubu-
lin isotype, Mß1 coding region in the plasmid pSVßl (Lewis et al ., 1987)
with the full-length TSG-6 cDNA . To exploit suitable restriction enzyme
sites foreasier cloning we used theM13mp18 vectorcarrying thefull-length
TSG-6cDNA at the EcoRI site, in either the sense or antisense orientation
with respect to lac promoter (Pi.) . A HindIII-Ncol fragment containing
the 5' region ofTSG-6cDNA was isolated from theantisense construct and
a Ncol-Kpnl fragment containing the3'region ofTSG-6cDNAwas isolated
from thesense construct. Both fragments wereligatedinto the HindIH/KpnI
cleaved plasmid pSVßl . The resulting expression construct (pSVTSG-6)
was used to cotransfectthe GM-637 cell line with pRSVneo (Gorman et al .,
1983), aplasmid that contains thebacterial neomycin resistance gene linked
to RSV LTR, by CaPO4-DNA precipitation (Graham and Van der Eb,
1973) . The transfected cells were given a 30-s glycerol shock by treat-
mentwith 15 % glycerol, and further incubated for 16 h . Thereafter, the cell
monolayers were replatedinmedium containing G418 (800 jig/ml) to select
for cells expressingthe neomycin resistance marker. Colonies were isolated
from transfection plates with the aid of cloning rings, subcloned in 24-well
plates, and expanded to monolayercultures. Multiple independent transfec-
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Figure 1. Northern blot analysis of TSG-6mRNA
expression in various types of cells. Cultures were
incubated for4 h with control medium orTNF (20
ng/ml) . Total RNA was isolated and fractionated
on 1% formaldehyde-agarose gels, transferred to
membranes, and hybridized with 32P-labeled TSG-6
cDNA and with the 32P-labeled pHe7cDNA insert
specific for an invariant N1.0-kb mRNA species .
(A) FS-4, human diploid foreskin fibroblasts ;GM-
637, SV40 virus-transformed human skin fibro-
blasts; U937, human macrophage-like histiocytic
lymphoma cell line; A673, human rhabdomyosar-
coma . (B) A549, human lung carcinoma ; Colo-
205, human colon adenocarcinoma ; HT29, human
colon adenocarcinoma; SK-MEL19, human cuta-
neous malignant melanoma . (C) WI-38 VA13, SV
40virus-transformedhuman fetal lung fibroblasts ;
FS-4 SVI, FS-4 SV2, and FS-4 SV3 are FS-4 lines
immortalized by transfectionofSV-40 1arge T anti-
gen (Wolchok J., G . Pecoraro, and J . Vil6ek, un-
published results) . (D) WI-38, human diploid fetal
lung fibroblasts.
tants were selected and tested forthe expression ofTSG-6mRNAby North-
ern blot analysis. The GSVL5 line, found to express the highest level of
TSG-6 mRNA, was used in the experiments.
PartialEnrichment ofTSG-6Protein byA ffinity
Chromatography on Sepharose-boundHA
Sepharose-bound HA was prepared essentially as described by Tengblad
(1979), except that the water-soluble coupling agentEDC was used injudi-
cious quantities to prevent excess modification of the carboxylic groups in
HA . We used 10 lumol EDC/100 mgHA per ml of EAH-Sepharose, so that
-1 out of25 carboxylic groupsinHA wouldbe coupled to the aminogroups
onthe beads. For the enrichment ofthe TSG-6protein, 300 nil ofthe condi-
tioned medium from GSVL5 cultures containing 10% serum was adjusted
to pH 5 .0 by adding 3 M sodium acetate (pH 4.6) and then applied onto
an HA-Sepharose column (2 ml bed volume) which had been equilibrated
with PBS containing 100 mM sodium acetate, pH 5.0 (APBS) .
Nonspecifically bound material was eluted with 15 ml APBS. Specifically
bound proteins were eluted with APBS containing 2 M NaCI plus 4 M
guanidine-HCI, dialyzed against PBS, and then stored frozen until used .
Coprecipitation ofTSG-6 Protein with
Glycosaminoglycans by Cetylpyridinium Chloride
To analyze the binding ofTSG-6protein toHA and other glycosaminogly-
cans, TSG-6 protein-glycosaminoglycan complexes were precipitated by
cetylpyridinium chloride (CPC) . 25-Al aliquots of the TSG-6 protein par-
tially enriched on HASepharose were mixed with 40 lug (in a final volume
of 120,ul in PBS) of. HA (H4015 ; Sigma Chemical Co.), chondmitin 4,6-
sulfate (C8529 ; Sigma Chemical Co.), dermatan sulfate (C4259; Sigma
Chemical Co.), heparan sulfate (H7640 ; Sigma Chemical Co.), heparin
547Figure 2. Northern blot analysis of TSG-6 mRNA expression in
HUVEC and mononuclear cells isolated from huPBL . Total RNA
was isolated and subjected to Northern blot analysis as in Fig . 1 .
(A) FS-4 cells and HUVEC were incubated for 4 h with control
medium (C) or TNF (20,ug/ml) . (B) HuPBL were incubated for
16 h with control medium (C) or TNF (20 ng/ml), Con A (5 Fg/
ml), or PHA (2 Fg/ml) .
(H3125 ; Sigma Chemical Co.), or dextran sulfate (17-0340-01; Pharmacia
Fine Chemicals) . After 1 h incubation at 37°C, 50 Wl of 2.5% CPC was
added to the samples and the mixtures were stirred and then incubated for
another 1 h at 37°C. After incubation, the mixtures were centrifuged for
15 min ina centrifuge (Eppendorf Inc., Fremont, CA) at maximum speed .
The pellets were carefully rinsed twice with 1% CPC containing 20mM
NaCl . The pellets were then dissolved in 100 pl SDS-PAGE sample buffer
(60mM Tris-HCI, pH 6.8,2% SDS, 10% glycerol, 7% 0-mencaptoethanol,
0.001% bromphenol blue) . The supernatants were also collected and
processed for electrophoresis. After fractionation on SDS-PAGE (12%
polyacrylamide), TSG-6 protein present in the pellets and supernatants was
visualized by Western analysis with the aid of affinity-purified anti-TSG-6
antibody.
Results
Expression ofTSG6 mRNA in Different Types
ofCells
TSG-6 cDNA was originally isolated from a cDNA library
prepared from TNF-treated cultures of normal human
diploid FS-4 foreskin fibroblasts (Lee etal ., 1990) . To deter-
mine what other cell types express TSG-6 message, we ex-
amined a large number ofcell lines for the presence of TSG-6
mRNA by Northern blot analysis (Fig . 1) . In each ofthe cell
lines RNA from both untreated and TNF-treated cultures
was examined . TSG-6 mRNA was not detectable in any of
the cell lines withoutTNF treatment . TSG-6mRNA became
readily detectable after TNF treatment in FS-4 cells (Fig . 1,
A-C) and in the WI-38 line of normal human fetal lung
fibroblasts (Fig. 1 D) . TNF treatment produced a similar in-
crease in steady-state TSG-6 mRNA levels in two other nor-
mal human foreskin fibroblast lines, designated FS-48 and
FS-49 (data not shown) . However, in none of the tumor-
derived cell lines (U937, A673, A549, Colo205, HT29, and
SK-MEL19) or SV-40-transformed fibroblast lines (GM-637
and WI-38VA13) was TSG-6 mRNA detectable after TNF
treatment (Fig . 1, A-C) . We also examined the inducibility
ofTSG-6 mRNA in cloned lines derived from the FS-4 cell
line after transfection with SV-40 large T antigen . Interest-
ingly, these cell lines, which display altered growth charac-
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teristics but do not appear to be fully transformed, showed
much lower levels of TSG-6 mRNA after TNF treatment
than the parental FS-4 cells (Fig. 1 C) . The lack ofTSG-6
mRNA induction seen in the fully transformed cells and the
decreased inducibility in the SV-40 T antigen-transfected
FS-4 lines were not the result ofa general lack ofresponsive-
ness of these cells to TNR For example, TSG44 mRNA
(Lee et al ., 1990) was more strongly inducible by TNF in
the SV-40T antigen-transfected FS-4 lines than in the origi-
nal FS-4 cells (data not shown) . Hence, it appears that induc-
tion of TSG-6 mRNA is suppressed in transformed cells .
We also examined the inducibility of TSG-6 mRNA by
TNF in normal HUVEC. The latter cells are known to be
highly responsive to TNF and several genes inducible by
TNF in normal fibroblasts were also inducible in HUVEC
cultures (Collins et al ., 1986 ; Holzman et al., 1990) . We
were therefore surprised to find thatTNF treatment failed to
induce the appearance ofTSG-6 mRNA in these cells (Fig .
2 A) . However, we were able to demonstrate an increase in
TSG-6 mRNA levels in cultures of freshly isolated periph-
eral blood human mononuclear cells after treatment with
TNF or after treatment with the T cell mitogens Con A or
phytohemagglutinin (Fig . 2 B) . Although the cell type
producing TSG-6 mRNA in the heterogeneous cultures of
mononuclear cells has not been identified, the latter results
show that induction of TSG-6 mRNAs is not restricted to
fibroblasts .
TSG6cDNA CodesforaPutative Protein with
Homology to Lymphocyte Homing Receptor CD44
and the CartilageLinkProtein Family
Full-length TSG-6cDNA was found to be 1,414 bases long,
apparently consisting of a 68-base 5'-untranslated region, a
continuous open reading frame of831 bases, and a 3'ATrich
untranslated region (-75% A+T content) (Fig . 3 A) . Within
the 3'-untranslated region are multiple mRNA destabiliza-
tion consensus sequence motifs AUUUA (Shaw and Kamen,
1986), which may account for the decline in the TSG-6
mRNA level seen after 4 h or more of continuous treatment
with TNF (Lee et al., 1990) . A consensus polyadenylation
signal (AATAAA) is also located at the 3' end . The largest
open reading frame predicts a polypeptide of 277 amino
acids with an estimated molecular weight of 31,200. No
other open reading frame with a significant length was
found . The putative initiation methionine is followed by 11
consecutive hydrophobic amino acids, followed by a charged
region, suggesting that this portion might form a cleavable
signal peptide (Fig . 3 B) . Following the (-3,-1) rule (von
Heijne, 1984), the putative signal sequence cleavage site will
be located after Gly'9. This would result in a mature form
of the protein with a predicted molecular weight of 28,895
and a calculated pl of 7.0. In addition, the predicted TSG-6
protein sequence contains two potential sites of N-linked
glycosylation (Asn' 18Arg-Ser and Asnua-Thr-Ser) . The se-
quence Ser°'-Gly preceded by an acidic amino acid (Glu")
is indicative of a potential chrondroitin sulfate linkage site
(Zimmermann and Ruoslahti, 1989) . It is also worth noting
that there is an aspartic acid-rich region (residue Asp"9 to
Asp2
1,) in addition to a serine- and threonine-rich region at
the COOH-terminal end ; the latter region includes six con-
secutive Ser/Thr residues (Thr2" to Thr26°), which may
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Figure 3. Nucleotide sequence
of TSG-6 cDNA and deduced
amino acid sequence. (A) Nu-
cleotide and amino acid residues
are numbered from the first me-
thionine of the major open read-
ing frame. The putative signal
sequence is underlined (thick
line). Potential glycosylation
sites for N-linked glycans are
shown by double broken lines.
Potential chondroitin sulfate
linkage site and consensus se-
quence are shown by star with
single broken line. Also under-
scored are the mRNA decay con-
sensus sequence motifs ATTTA
(thin line) and the polyadenyla-
tion signal (mm). These se-
quence data are available from
EMBL/GenBank/DDBJ under
accession number M31165. (B)
Hydropathic profile of the de-
duced amino acid sequence of
TSG-6 using the algorithm of
Kyte and Doolittle (1982) .
-68 ga att cgc -61
-60 act get ctg aga att tgt gag cog ccc cta aca ggc tgt lac ttc act aca act gac gal -1
1 ATG ATC ATC TTA ATT TAC TTA TTT CTC TTG CTA TGG GAA GAC ACT CAA GGA TGG GGA T'TC G0
1 Met Ile Ile Leu Ile Tyr Leu Plie Leu Leu Leu Trp Glu Asp Tlir Gln Gly Trp Cly Plie 2.0
61 AAG GAT GGA ATT TTT CAT AAC TCC ATA TGG CTT GAA CGA GCA GCC GGT GTG TAC CAC AGA 12()
21 Lys Asp Gly Ile Phe His Asn Ser Ile Trp Leu Glu Arg Ala Ala Gly Val Tyr His Arg 40
121 GAA GCA CGG TCT GGC AAA TAC AAG CTC ACC TAC GCA GAA GCT AAG GCG GTG TGT GAA TTT 180
41 Glu Ala Arg Ser Gly Lys Tyr Lys Leu Thr Tyr Ala Glu Ala Lys Ala Val Cys Glu Plie 60
-------------*-----
181 GAA GGC GGC CAT CTC GCA ACT TAC AAG CAG CTA GAG GCA GCC AGA AAA ATT GCA TTT CAT 240
61 Glu Gly Gly His Leu AU Thr Tyr Lys Gln Leu Glu Ala Ala Arg Lys lle Gly l'lie Ilis 80
241 GTC TGT GCT GCT GGA TGG ATG GCT AAG GGC AGA GTT GGA TAC CCC ATT GTG AAG CCA GGG 300
81 Val Cys Ala Ala Gly Trp Met Ala Lys Gly Arg Val Gly Tyr Pro Ile Val Lys Pro Gly 100
301 CCC AAC TGT GGA TTT GGA AAA ACT GGC ATT ATT GAT TAT GGA ATC CGT CTC AAT AGG AGT ',60
101 Pro Asn Cys Gly Phe Gly Lys Thr Gly Ile Ile Asp Tyr Gly Ile Arg Leu Asn Arg Sur 120
361 GAA AGA TGG GAT GCC TAT TGC TAC AAC CCA CAC GCA AAG GAG TGT GGT GGC GTC TTT ACA 4211
121 Glu Arg Trp Asp Ala Tyr Cys Tyr Asn Pro His Ala Lys Glu Cys Gly Gly Val Plie Thr 14(1
421 GAT CCA AAG CGA ATT TTT AAA TCT CCA GGC TTC CCA AAT GAG TAC GAA GAT AAC CAA ATC 1.80
141 Asp Pro Lys Arg Ile Phe Lys Ser Pro Gly Phe Pro Asn Glu Tyr Glu Asp Asn Gln Ile 16(1
481 TCC TAC TGG CAC ATT AGA CTC AAG TAT GGT CAG CGT ATT CAC CTG ACT T'TT TTA CAT T'TT I,ß.0
161 Cys Tyr Trp His Ile Arg Leu Lys Tyr Gly Gln Arg Ile His Leu Sec Plie Leu A.sl+ Plie ltio
541 GAC CTT CAA GAT GAC CCA GGT TGC TT'G GCT GAT TAT GTT GAA-ATA TAT GAC AGT 1AC GAT (lui
181 Asp Leu Glu Asp Asp Pro Gly Cys Leu Ala Asp Tyr Val Glu Ile Tyr Asp Ser 'ryr Asp 20(1
601 GAT G'TC CAT GCC TTT GIG CCA AGA TAC TCT CCA CAT GAG t:TT CCA CAT GAC ATC ATC ACT 660
201 Asp Val His Gly Phe Val Gly Arg Tyr lays Gly Asp Glu Lcu Pro Asp Asp Ile Ile Sur 220
661 ACA GGA AAT GTC ATG ACC TTG AAG T'TT CTA AG'r GAT GCT TCA GTG ACA GCT GCA GGT TTC 770
221 Thr Gly Asn Val Met Thr Leu Lys Phe Leu Ser Asp Ala Ser Val T'hr Ala Gly Gly Phe 240
721 CAA ATC AAA TAT CTT CCA ATG GAT CCT GTA TCC AAA TCC ACT CAA GGA AAA AAT ACA AGT 700
241 Glri Ile Lys Tyr Val Ala Met Asp Pro Val Ser Lys Ser Si_r Gln Gly Lys A:ai 1'hr Ser 260
701 ACT ACT TCT ACT GGA AAT AAA AAC TTT TTA GCT GGA AGA TTT Arc CAC TTA laa aaa aaa 840
261 Thr Thr Ser Thr Gly Asti Lys Anti Plie Leu Ala WY Arg ['he Ser His Leu 277
841 aaa agg, atg atc aaa aca cac agt gtt tat gtt gga ate ttt tgg aac tee ttt gat etc 900
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serve as acceptors for O-linked carbohydrates (Tomita et al . ,
1978).
Comparison of the amino acid sequence deduced from the
TSG-6 cDNA with the protein sequences available in data-
bases revealed interesting homologies (Fig. 4) . The NHz-
terminal half of the putative TSG-6 gene product shows a
high degree of homology with the human lymphocyte hom-
ing receptor/HA receptor CD44 (Goldstein et al., 1989;
Stamenkovic et al., 1989), human cartilage link protein
(Dudhia and Hardingham, 1989; Doege et al., 1990x), and
the human proteoglycan core proteins versican (Zimmer-
mann and Ruoslahti, 1989) and aggrecan (Doege et al.,
1990b), with the positions of four cysteine residues con-
served in all of these proteins (Fig. 4 A) . Based on the align-
ment shown in Fig. 4 A, this portion of the predicted TSG-6
protein (residues 36-127) shows ti37 % identity with CD44,
36% identity with cartilage link protein, and 40% identity
with the proteoglycan core proteins versican and aggrecan.
The highest degree of homology (~60%) exists between a
limited region (CysB' to Proms) of the TSG-6 cDNA-encoded
protein and a corresponding region of link protein and pro-
teoglycan core proteins. The conserved basic amino acids in
this region have been implicated in an ionic-type interaction
with the negatively charged uronic acid residues in HA
(Hardingham et al. , 1976; Lyon, 1986; Goetinck et al. ,
1987) . No significant sequence homology was found be-
tween the TSG-6 protein and most other members of this
family upstream of G1y36 or downstream of Cys'z' in TSG-6.
However, sequence homology between the TSG-6and CD44
proteins extends over wider portions of the two molecules.
An alignment of residues 33-142 of TSG-6 with a homolo-
gous portion of CD44 reveals 37 % identity (Fig. 4 B). In ad-
dition, the COOH-terminal half of TSG-6 (Fig. 4 C) shows
N30% sequence homology with the a-fragment of comple-
ment Clr A chain (Leytus et al ., 1986).
The predicted secondary sequence of the TSG-6 protein
(Fig. 5) reveals that the region homologous to CD44, link
protein, and the proteoglycan core proteins forms an ex-
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tended loop involving two disulfide bonds, conserved in all
of these proteins. This loop structure was shown to form the
HA binding domain of link protein (Goetinck et al., 1987),
and is also thought to be responsible for HA recognition in
the other proteins in this family (Perm et al. , 1987; Culty et
al. , 1990).
TSG-6 Is a Secretory Protein
As a first step toward the characterization of the protein
coded for by the TSG-6 cDNA, we immunized rabbits with
an E. coli-derived fusion protein composed of portions of
the E. coli TrpE and TSG-6 proteins. The resulting antibody
was purified by adsorption and elution on a Sepharose
column to which a MS2/TSG-6 fusion protein was coupled
(see Materials and Methods). We also constructed a consti-
tutive expression plasmid pSVTSG-6 containing the com-
plete TSG-6 coding region (see Materials and Methods).
This expression construct was used to transfect the GM-637
cell line, together with the pRSVneo plasmid containing the
bacterial neomycin resistance gene. The GM-637 line was
earlier shown not to express detectable endogenous TSG-6
mRNA (see Fig. 1 A). After clonal isolation, the GSVLS
line that constitutively expressed a high level of TSG-6
mRNAwas chosen for the analysis of the presence ofTSG-6
protein.
Fig. 6 A (top) shows that no immunoreactive band was de-
tected by Western blot analysis of a concentrated culture su-
pernatant ofGM-637 cellstransfected with plasmid pRSVneo
alone (marked "GN4r). In conVast, two immunoreactive
bands were present in the supernatant of the GSVLS line,
transfected with the TSG-6 cDNA-containing expression
vector. The faster migrating band, with an apparent molecu-
lar mass of 39 kD on SDS-PAGE, may represent the glyco-
sylated form of the TSG-6 protein. (The molecular mass of
the mature TSG-6protein based on the primary sequence is
N29 kD.) In addition, a slower migrating immunoreactive
band (>110 kD) was detected.To determine whether the TSG-6 protein was also detect-
able in the FS-4 fibroblast line, cultures were either stimu-
lated with 20 ng/ml TNF or left untreated . After 24 h the
medium was collected and concentrated -100-fold in an
Amicon apparatus (Amicon, Beverly, MA) . Samples were
subjected to Western blot analysis, side-by-side with the
samples of cultures transfected with the TSG-6 expression
vector (Fig . 6 A, top) . A major 39-kD band and a minor
>110-kD band were detected by the affinity-purified antise-
rum in the culture supernatant of TNF-treated FS-4 cells
(lane marked FS-4 (T)), but not in control FS-4 cultures
(marked FS-4 (C)) . The two bands seen in the supernatant
ofTNF-stimulated FS-4 cells were identical to the bands de-
tected in themedium ofGSVL5 cultures . As also seen with
GSVL5 cells (cf. Fig. 6,A and B), the proportion ofthe 39-
kD and >110-kD bands detected in the media from TNF-
treated FS-4 cells varied from one experiment to another
(not shown) . No bands were detected in either GSVL5 cul-
tures or TNF-stimulated FS-4 cells when identically pro-
cessed preimmune serum from the same rabbit was used in
Western blot analysis (Fig . 6 A, bottom) . Taken together,
these results indicate that both the 39-kD and the >110-kD
bands detected by the immune serum represent products of
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Figure 5. Schematic diagram oftheputative second-
ary structure ofTSG-6 protein . The predicted signal
peptide, the domain Gly 36 to Cys127 showing ho-
mology with theHA binding regions of CD44, link
proteins, andproteoglycan coreproteins, andthe do-
main Gly' 36 to Phe2^° showing homology to comple-
mentOra fragmentare highlighted by crosshatch-
ing . Also depicted are two potential N-glycosylation
sites (ball andstick) and a potential chondroitin sul-
fate linkage site (square box and stick) . Disulfide
linkages (Cys58-Cys' 27 and Cysa2-Cys' o3) are based
on the known disulfide bonds in theHA binding do-
mains of link protein and other proteoglycan core
proteins . Disulfide linkage (Cys'$e-Cyst'°) is based
on the known disulfide bond in complement Or.
Predicted disulfide bond formation between Cys' 35
and Cys'6' is hypothetical because no cysteine resi-
due corresponding to Cys'61 in the TSG-6 protein
is present in complement Or.
the TSG-6 gene . Subsequent analysis indicated that the ap-
parent molecular mass of the >110-kD band is -120kD (see
Fig . 7), suggesting that it may represent either an undis-
sociated trimeric form ofTSG-6 or a complex ofTSG-6 with
another protein . Since SDS-PAGE separations were run un-
der reducing conditions (7% ß-mercaptoethanol), it is un-
likely that intermolecular disulfide linkage accounted for the
formation of the 120-kD form .
While a 39-kD immunoreactive band was readily detect-
able in the concentrated culture medium ofGSVL5 cells, a
cell extract from the same cultures failed to reveal the pres-
ence ofTSG-6 protein (Fig. 6B) . Similarly, we were unable
to detect the TSG-6 protein in extracts of TNF-treated FS-4
cultures (not shown) . These data suggest that, once synthe-
sized, TSG-6 protein is rapidly secreted into the culture
medium . These findings are in agreement with the presence
of a cleavable signal peptide, predicted from the deduced
amino acid sequence (Fig . 3, A and B) .
TSG6 Is a Glycoprotein
Inasmuch as the deduced amino acid sequence of theTSG-6
protein predicts two potential N-glycosylation sites, the pres-
ence of N-linked carbohydrate was analyzed by N-glycosi-
552dase F treatment. TSG-6 protein from GSVL5 cell culture
supernatants was first partially purified by affinity chroma-
tography (see Materials and Methods) and then treated with
16.7 U/ml N-glycosidaseF at 37°C for different times. A 3-h
incubation with theenzyme resulted in the disappearance of
the 39-kD band and the appearance of two bands with appar-
ent molecular masses of 36 and 33 kD, respectively (Fig. 7) .
After overnight treatmentwith 16.7 U/mlN-GycosidaseF the
36-kD band was no longer detectable and all of the 39-kD
Figure 7 . Reductionin the apparent molecu-
lar size of TSG-6 protein after N-glycosi-
dase F treatment . TSG-6 protein, partially
purified by affinity chromatography (see
Materials and Methods), was incubated
with 16.7 U/ml N-glycosidase F (left lane)
or without enzyme (right lane) at 37°C for
3 h. Western blot analysis was performed
after SDS-PAGE on a 4-15% polyacryl-
amide gradient gel .
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Figure 6. Detection of TSG-6
protein in cultures of TNF-
treated FS-4 cells and inGM-
637 cells transfected with
TSG-6 cDNA (GSVL5) by
Western blot analysis . (A)
Serum-free medium collected
from TNF-treated FS-4 cells
or TSG-6 cDNAtransfected
GSVL5 cells was concentrated
-100-fold . The samples were
analyzed by SDS-PAGE (12%
polyacrylamide) . In the upper
panel (IMM), bands were de-
veloped with the aid of anti-
TSG-6 antibody purified by
affinity chromatography as
described in Materials and
Methods. In the lower panel
(PRE), bands were developed
with similarly processed pre
immune serum from the same rabbit. GN4, supernatant ofGM-637
cells transfected with pRSVneo ; GSVL5, supernatant of GM-637
cells transfected with pSVTSG-6 ; FS-4 (C), supernatant of un-
treated FS-4 cells ; FS-4 (T), supernatant of FS-4 cells treated for
24 h with TNF (20 ng/ml) . Molecular weight standards are indi-
cated to the left ofthe toppanel and to the right ofthe bottompanel .
(B) Western blot analysis showing that TSG-6 protein is detectable
in the culture medium of GSVL5 cells, but not in cell lysates .
Serum-free mediumcollected from cultures ofGN4 cellsorGSVL5
cells was concentrated -100-fold in an Amicon apparatus (PM10
membrane) . Tb prepare lysates, cells from a 175-cm2 flask were
treated with -0.5 ml SDS-PAGE sample buffer (60mM Tris-110,
pH 6.8, 2% SDS, 10% glycerol, 7% 0-mercaptoethanol, and
0.001% bromphenol blue) . The samples were then subjected to
Westernblot analysis with the aid ofaffinity-purified anti-TSG-6 an-
tibody. Sup, supernatants ofGN4 orGSVL5 cultures, concentrated
-100-fold ; Ext, lysates of GN4 or GSVL5 cells .
form was apparently converted into the 33-kD band (not
shown) . These data suggest that the 36-kD band corresponds
to a partially deglycosylated form, and the 33-kD band to
a monomeric form of TSG-6 protein completely devoid of
N-linked carbohydrate . These results are consistent with
the predicted presence of two N-glycosylation consensus se-
quences in the TSG-6 protein (Figs. 3 A and 5) . Glycosidase
treatment also resulted in a decrease ofthe higher molecular
weight band recognized by antibodies to the TSG-6 protein,
from an apparent molecular mass of -120 kD to -110 kD
(Fig . 7) .
In view of the presence of a potential chondroitin sulfate
linkage site, as noted above (Figs. 3A and 5), we also exam-
ined the effect of chondroitin sulfate ABC lyase (chon-
droitinase ABC) on the apparent molecular size of TSG-6
protein produced in GSVL5 cultures. The latter treatment
resulted in no demonstrable change in the migration pattern
of the 120- or the 39-kD band recognized by the antibody
to TSG-6 (data not shown), suggesting the absence of a
linked chondroitin sulfate moiety.
TSG6 Is aHyaluronateBindingProtein
In view of the high degree of homology with the domain
responsible for HA binding in CD44 and the cartilage link
553Figure 8. Effect of varying concentrations of hyaluronate on the
coprecipitation of TSG-6 protein by CPC. A constant amount of
TSG-6 protein partially enriched by affinity chromatography on
HA coupled to Sepharose was mixed with varying concentrations
ofHA for 1 h andprocessed as described in Materials and Methods .
Constant glycosaminoglycan concentration (330 lg/ml) was main-
tained by adding varyingamounts ofchondroitin sulfate as a carrier.
Western analysis was performed to visualize TSG-6 protein bound
to HA in the precipitate (ppt) as well as unbound TSG-6 protein
in the supernatant (sup) . The 120- and 39-kD bands of the TSG-6
protein are marked with arrows .
protein family (Figs . 4A and 5), it seemed plausible that the
TSG-6 protein too is anHA binding protein . To test this no-
tion we first determined whether TSG-6 protein would bind
to HA immobilized on Sepharose beads. It has been known
that HA binding proteins, such as proteoglycan core protein
and cartilage link protein, can be purified by affinity chroma-
tography on immobilized HA (Tengblad, 1979) . Since HA
is a linear polysaccharide built from repeating disaccharide
units consisting of D-glucuronic acid and N-acetyl-D-glucos-
amine, every carboxylic group of D-glucuronic acid unit in
HA can be potentially modified by the coupling agent EDC
and immobilized to the amino group ofEAH-Sepharose . To
prevent complete modification of the carboxylic groups in
HA we used a subeffective concentration ofEDC (10 pmol/
100mg ofHA), so that til out of every 25 carboxylic groups
would be modified and coupled to the functional amino
groups of EAH-Sepharose . Using this approach, we were
able to effectively enrich theTSG-6 protein from the condi-
tionedmedium ofGSVL5 cultures by column affinity chro-
matography on EAH-Sepharose coupled with HA (HA-
Sepharose) . In addition, we were able to partially block the
binding of TSG-6 protein to HA-Sepharose by adding solu-
bleHA, but not by soluble chondroitin sulfate, when the two
glycosaminoglycans were used at the same concentration of
1 mg/ml (data not shown) .
To address more directly the specific interaction between
TSG-6 protein and HA we attempted to coprecipitate TSG-6
protein with HA and other glycosaminoglycans (chondroitin
4,5-sulfate, dermatan sulfate, heparan sulfate, and heparin) .
It has been shown that glycosaminoglycans can be precipi-
tated by cationic detergents such as CPC as a result ofbulky
salt formation between the two molecules (Scott, 1961) . We
reasoned that if the TSG-6 protein interacts with HA through
specific recognition of sugar residues as well as through an
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ionic interaction, then theTSG-6 protein could be coprecipi-
tated more efficiently with HA than with other glycosamino-
glycans . This prediction was essentially borne out . TSG-6
protein from a culture supernatant of GSVL5 cultures was
enriched by affinity chromatography on HA-Sepharose, as
described in Materials and Methods. A constant amount of
the enrichedTSG-6 protein was incubated with varying con-
centrations ofHA and/or chondroitin sulfate (Fig. 8) . CPC
was then added to all samples and the resulting precipitates
were sedimented by centrifugation . The pellets as well as the
supernatants were then analyzed for the presence ofTSG-6
protein by Western blotting . HA produced a concentra-
tion-dependent coprecipitation of the 120- and 39-kD bands
ofTSG-6 . Addition of chondroitin sulfate caused no copre-
cipitation, nor did the presence of chondroitin sulfate affect
coprecipitation with HA . Since chondroitin sulfate carries a
stronger negative charge than HA, this result suggests that
the binding ofTSG-6 to HA is not due solely to a simple
ionic interaction .
Similar coprecipitation experiments were also carried out
withTSG-6 and dermatan sulfate, heparan sulfate, and hepa-
rin (not shown) . When used at concentrations up to 2.5 mg/
ml, dermatan sulfate (like chondroitin sulfate) produced no
detectable coprecipitation oftheTSG-6 protein (not shown) .
Heparan sulfate and heparin, though clearly less effective
than HA when used at the same concentrations, at higher
concentrations produced a partial coprecipitation ofthe 120-
kD band with little or no coprecipitation of the 39-kD band
of the TSG-6 protein . Taken together, these results suggest
that interaction ofTSG-6 protein with HA involves a recog-
nition of sugar residues specific to HA, perhaps together
with an ionic-type interaction .
Discussion
TNF-a and the functionally related cytokines IL-la and IL-
lß play major roles in the inflammatory processes (Balkwill,
1989) . Although many different cell types can be induced to
produce TNF-a, IL-la, and IL-lß, in the intact organism
their main sources appear to be monocytes and macrophages
(Le and Vi1Zek, 1987 ; Dinarello, 1988 ; Vil6ek and Lee,
1991) . All three cytokines are characteristically produced at
sites of inflammation ; they play beneficial roles as im-
munoregulators, mediators of host resistance, and promot-
ers of tissue repair. On the other hand, overproduction of
TNF or IL-1 during inflammation can lead to tissue damage
and systemic toxicity (Balkwill, 1989) . Earlier we reported
the isolation of eight distinct cDNAs from a cDNA library
prepared from TNF-a-treated normal human FS-4 foreskin
fibroblasts (Lee et al., 1990) . All eight cDNAs correspond
to mRNAs whose levels are either undetectable or very low
in untreated FS-4 cells, and are significantly increased upon
the exposure of cells to either TNF or IL-1 . Partial sequenc-
ing of these cDNAs revealed that four of them represent
known genes, namely, IL-8 (a cytokine whose major role
is thought to be chemotactic activity for neutrophils and
T cells), monocyte chemotactic and activating factor (a
cytokine structurally related to IL-8), and the metallopro-
teinases collagenase and stromelysin, respectively (Lee et
al ., 1990) . Subsequently, a fifthcDNA (TSG-37) was found
to be identical to metallothionein II (Lee, T. H ., and G . W.
Lee, unpublished data) . The three remaining cDNAs could
554not be matched with DNA sequences available in databanks,
suggesting that they correspond to novel genes.
In this paper we describe the characterization ofone ofthe
novel cDNAs, termed TSG-6. The largest open reading
frame predicted a polypeptide of 277 amino acids, including
a characteristic hydrophobic signal peptide sequence (Fig.
3). The putative amino acid sequence deduced from the
TSG-6 cDNA revealeda significant degree ofhomology with
a conserved region present in a recently identified family of
proteins (Fig. 4) that includes the HA receptor/lymphocyte
homing receptor CD44 (Goldstein et al., 1989; Stamenko-
vic et al., 1989), cartilage link protein (Dudhia and Hard-
ingham, 1989; Doege et al ., 1990a), and the proteoglycan
core proteins versican (Zimmermann and Ruoslahti, 1989)
and aggrecan (Doege et al., 1990b). The homologous re-
gion, thought to comprise the HA binding domain (Goetinck
et al., 1987; Perin et al., 1987; Culty et al., 1990), is tan-
demly repeated in the cartilage linkprotein and proteoglycan
core proteins, while being represented only once in CD44
(Goldstein et al ., 1989; Stamenkovic et al., 1989) as well as
in TSG-6 (Figs. 3 and 5) . The degree of sequence homology
between TSG-6 and the other human proteins of this family
is of a similar magnitude as the homology of the other mem-
bers of this family to each other. Based on a similar align-
ment of the sequences ofhuman CD44 with rat and chicken
cartilage link proteins (showing a homology of -30%),
Stamenkovic et al . (1989) calculated that the probability of
an equal or better match occurring between unrelated pro-
teinswas <10-'s. Interestingly, the homology between TSG-6
and CD44 extended over regions of the two proteins that
showed no significant homology with the other members of
this protein family (Fig. 4B). This finding suggests a closer
evolutionary relationship of TSG-6 to CD44 than to the car-
tilage link and proteoglycan core proteins. The homologous
sequences in the TSG-6 and CD44 proteins may have di-
verged from the same ancestral gene before duplication of
this domain in the proteoglycan core and cartilage link pro-
teins, or they may have been derived from one of these do-
mains (Goldstein et al., 1989).
Antibodiesgenerated against a bacterial fusion protein of
TSG-6 were used to demonstrate the presence of TSG-6 pro-
tein in the culture medium of cellstransfected with a TSG-6
expression vector or in FS-4 fibroblasts treated with TNF
(Fig. 6). The 39-kD band defined by the antibodies appar-
ently represents the fully glycosylated mature monomeric
form of TSG-6 protein. The generation of two faster migrat-
ing bands (36 and 33 kD, respectively) after treatment with
N-glycosidase F (Fig. 7) is consistent with the presence of
two potential N-glycosylation sites in the coding sequence.
The apparent molecular weight of TSG-6 protein after
prolonged treatment with N-glycosidase F (33 kD) is some-
what greater than the predicted molecular weight of 28,895
of the unglycosylated mature polypeptide. This small dis-
crepancy could be due to incomplete deglycosylation (e.g.,
presence ofO-linked carbohydrate) or to slightly anomalous
migration characteristics on SDS-PAGE.
A higher molecular weight form with the apparent size of
-120 kD was also detected by the anti-TSG-6 antibody in the
culture media of GM-637 cellstransfected with TSG-6 cDNA
and ofTNF-treated FS-4 cells (Figs. 6A, 7, and 8) . Although
all SDS-PAGE separations were done under reducing condi-
tions, the proportions between the 120- and 39-kD forms
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varied from experiment to experiment. The 120-kD form
may represent an undissociated complex of TSG-6 with a
putative carrier molecule or a tightly held TSG-6 homotrimer.
Since the predicted sequence of the protein indicated that
TSG-6 is a member of the family of HA binding proteins,
we sought to determine whether the TSG-6 protein too can
bind HA. TSG-6 protein secreted into the medium of GM-
637 cells transfected with a TSG-6 expression vector was
partially purified by adsorption and elution on Sepharose-
bound HA. That binding to HA involves more than a simple
ionic interaction is supported by the experiments in which
we demonstrated coprecipitation of the TSG-6 protein with
HA by the cationic detergent CPC (Fig. 8). These experi-
ments indicate that CPC, which interacts with the polyan-
ionic glycosaminoglycans through an ionic-type interaction,
did not causedissociation of the complexes formed between
TSG-6 and HA. The failure of CPC to coprecipitate TSG-6
mixed with chondroitin-4,5-sulfate or dermatan sulfate sug-
gests a weaker and less specific interaction between TSG-6
and these glycosaminoglycans. It is interesting that TSG-6
protein was not coprecipitated with chondroitin-4,5-sulfate
and dermatan sulfate (Fig. 8 and data not shown), even
though they share with HA the common structural feature of
alternating ßl-3 and ßl-4 bonds and have an even higher
charge density because oftheir sulfation. On the other hand,
heparan sulfate, which differs from HA considerably by hav-
ing alternating al-4 and ßl-4 bonds but shares with HA
the content of N-acetylglucosamine, seems to interact with
TSG-6 protein stronger than some other glycosaminogly-
cans, though not as strongly as HA (not shown) .
What is the biological function of the TSG-6 protein? The
finalanswer to this question will have to await the results of
experiments with purified TSG-6 protein. In view of its ho-
mology with CD44 and demonstrated ability to interact with
HA, secretory TSG-6 protein couldact as a competitive in-
hibitor of the interaction between CD44 and its ligand(s).
Although CD44 is thought to represent the principal HA
receptor, expressed on a wide variety of cells (Stoolman,
1989 ; Underhill, 1989), some functions of CD44 may not
depend on its ability to bind HA (Carter and Wayner, 1988;
Culty et al ., 1990) . Hence it is conceivable that the biologi-
cal functions of TSG-6 also are not limited to situations in
which binding to HA is involved. Even if interaction with
HA would not be central to its biological function, binding
of TSG-6 to HA might act as a means to efficiently concen-
trateTSG-6 in the extracellular matrix, in the vicinity of its
target cells. Future experiments will seek to determine
whether TSG-6 can compete with CD44 for binding to HA,
and also whether TSG-6 can affect lymphocyte homing
mediated by the interaction of CD44 with a still incom-
pletely characterized mucosal vascular addressin (Jalkanen
et al., 1987; Stoolman, 1989).
Inducibility by TNF or IL-1 suggests a role for TSG-6 in
inflammation. In BCG-induced granulomatous inflamma-
tion, TNF released from macrophages plays a crucial role
in the aggregation and activation of macrophages, leading to
the development ofgranulomas (Kindler et al., 1989). In ad-
dition, an increase in HA was found in the early stage of the
BCG-induced granulomatous response in the rabbit lung
(Loveet al., 1979)and in delayed-type hypersensitivity reac-
tions (Shannon and Love, 1980; Campbell et al., 1982). The
interaction between HA and CD44 is thought to be involved
555in macrophage aggregation (Green et al., 1988). Hence, it
is conceivable that the TSG-6 protein, induced by TNF or
IL-1 in the microenvironment of inflammatory granulomas,
modulates the aggregation and activation of macrophages
mediated by the HA-CD44 interaction. It is also of interest
that TNF and IL-1 increase the amount of HA secreted by
human synovial fibroblasts (Butler et al ., 1988) . Local ac-
cumulation ofHA may facilitate cell migration to sites of in-
jury, modulate cell proliferation, and regulate inflammatory
and immune cell responses by effects on antigen and/or me-
diator binding (Laurent and Fraser, 1986; Whiteside and
Buckingham, 1989; Meyer et al ., 1990). TSG-6 also could
play a role in the modulation of these processes.
The presence of a shared HA binding domain in TSG-6,
cartilage link protein, and proteoglycan core proteins sug-
gests a possible involvement of TSG-6 in the structural orga-
nization ofthe extracellular matrix of connective tissue. The
structural integrity of cartilage is maintained by the ternary
complex involving proteoglycan, link protein, and HA (Has-
call and Hascall, 1981) . Cartilage breakdown occurs in rheu-
matoid arthritis, osteoarthritis, and other joint diseases as a
result of destabilization of the ternary complex. TNF and
IL-1 are known to cause proteoglycan degradation, leading
to cartilage breakdown (Saklatvala, 1986; Shinmei et al.,
1989). It is conceivable that TSG-6 protein induced by TNF
or IL-1 during inflammation could interact with link protein
or proteoglycan core protein through the shared homologous
domain, resulting in a destabilization ofthe proteoglycan ag-
gregates.
Sinceboth TNF and IL-1 are mitogenic for normal fibro-
blasts (Schmidt et al., 1982; Sugarman et al ., 1985 ; Vil6ek
et al ., 1986), generation of TSG-6 could be related to the
processes of wound healing, tissue repair, and fibrosis. It is
intriguing that none of the transformed cells examined by us
was found to contain demonstrable TSG-6 mRNA (Fig. 1).
The lack of TSG-6 expression in tumor cell lines contrasts
with the high level of CD44 mRNA expression in many
transformed cells (Stamenkovic et al ., 1989). The involve-
ment ofHA and the cellular HA receptor in transformation,
invasive growth, and metastasis has been well established
(Knudson et al., 1989). Invasiveness oftumor growth corre-
lates with increased amounts of HA in the tumor and in the
interface to the surrounding connective tissue (Toole et al.,
1979) . Virus-transformed cells showed an increased HA
binding capacity compared with the parental cell lines (Un-
derhill and Toole, 1981). A highly invasive bladder carci-
noma also showed a high degree of HA binding (Nemec et
al., 1987) . Finally, Günthert et al. (1991) recently showed a
causal relationship between the expression of a novel splic-
ing variant of CD44 and the metastatic potential of rat tumor
cell lines. Inasmuch as TSG-6binds to HA, it is conceivable
that TSG-6 is involved in the modulation of these processes,
possibly as a competitive inhibitor of CD44 binding to HA.
In conclusion, we have identified a novel inflammatory
cytokine-inducible gene, termed TSG-6, coding for a protein
that includes a unique loop domain homologous to a se-
quence in the HA receptor/lymphocyte homing receptor
CD44, cartilage link protein, and proteoglycan core pro-
teins. Mature TSG-6 is a secreted protein whose apparent
molecular mass is 39 kD in monomeric form. It is glyco-
sylated at two N-linked glycan acceptor sites. We have shown
that the TSG-6 protein bindsHA. Together these characteris-
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tics suggest that TSG-6 plays a role in cell-cell or cell-cell
matrix interactions during inflammation and tumorigenesis.
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